A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

NCT01108458 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Extreme toxicity of Pertuzumab and Erlotinib combination

Conditions

Pancreatic Cancer

Interventions

DRUG: Pertuzumab
DRUG: Erlotinib

Sponsor

George Albert Fisher

Collaborators

[object Object]